Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid‐19

• DOI: 10.1111/trf.15975
• Publication Date: 2020-08-08T11:01:28Z
• Authors: Miao Liu; Zhen Chen; Meng‐Yuan Dai; Jun‐Hui Yang; Xiao‐Bing Chen; Di Chen; Hua You; Xin Guo; Yan Leng; Li Yu; Meng‐Li Zhang; Xian Wu; Junyu Yang; Chong Gao; Daniel G Tenen; Li Chai; Fen Ai
• Keywords: Convalescent plasma; Cytokine Storm

Abstract Background The management of critically ill patients with coronavirus disease 2019 (COVID‐19), caused by a new human virus severe acute respiratory syndrome 2 (SARS‐CoV‐2), is challenging. Recently, there have been several reports inconsistent results after treatment convalescent plasma (CP) on COVID‐19, which was produced neutralizing antibody titer and tested in P3 or P4 laboratory. However, due to the limitation conditions mass production plasma, most producers hardly had capability isolate antibody. Here, we report clinical courses three COVID‐19 receiving CP treatments total immunoglobulin G (IgG) collection. Methods Three this study were laboratory confirmed be positive for SARS‐CoV‐2, radiographic features pneumonia. collected IgG 160 (range, 200‐225 mL), transfused between 20 30 days onset at critical illness stage as trial addition standard care. these patients, including pulmonary functional image studies infusions, reviewed. Results No therapeutic effect observed any patients; instead, all deteriorated required extracorporeal membrane oxygenation treatment. A potential cytokine storm 4 hours infusion Patient observed. more put transfusion. Conclusions We recommend extreme caution using than weeks